Pharma BD Deal Intelligence
Duke Collier, incoming president of Genzyme Biosurgery: 'a combination of very strong device-selling skills and biotechnology product development is a pretty…
Hyaluronic-acid intra-articular injections were FDA-approved for knee OA but later meta-analyses found only minor benefit, framing Synvisc as a category leader…
Genzyme acquired Biomatrix in 2000, combining it with Genzyme Tissue Repair and Genzyme Surgical Products to form the Genzyme Biosurgery tracking-stock…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Genzyme acquired Biomatrix in a cash-and-stock deal valued at ~$700M (cash component ~$245M at $37/share for 28.4% of shares, stock for the balance). Combined with Genzyme Tissue Repair and Genzyme Surgical Products to create Genzyme Biosurgery tracking-stock entity. Closed Dec 18, 2000.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme Corporation / Biomatrix Inc. (this deal) | 2000 | $700M | 65 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
| Genzyme Corporation / Novazyme Pharmaceuticals Inc. | 2001 | $138M | 54 |
| Genzyme Corporation / Verigen AG | 2005 | $50M | 29 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2000 deals · Genzyme Corporation deals · Other deals